-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Science and Technology Innovation Board allows unprofitable companies to go public, allowing a group of hard-core pharmaceutical and biological companies to show their “hard technology”
.
Now, it has been three years since the launch of the Sci-tech Innovation Board in 2019.
In these three years, the number of pharmaceutical and biological companies listed on the Sci-tech Innovation Board has continued to hit new highs, from 14 listed in 2019 to 28 in 2020.
Up to now, the number of pharmaceutical companies that have successfully listed on the Science and Technology Innovation Board has reached 34
.
In summary, the sci-tech innovation board pharmaceutical companies listed this year include Novartis, Dizhe Pharmaceutical, Zhijiang Biological, Chengda Biological, Beike Biological, Olin Biological, Haoyuan Pharmaceutical, etc.
, mainly focusing on chemical pharmaceuticals and medical devices.
Subdivisions such as, biological products, medical services, etc.
, each have their own characteristics, and have also revealed "hard technology" in R&D
.
In terms of market value, there are 13 pharmaceutical companies with a new market value of more than 10 billion yuan
.
Among them, the bio-reagent giant Novartis, which was listed on November 15 this year, has a market value of 46.
273 billion yuan
.
This is a biotechnology company that conducts technology research and development and product development around functional proteins such as enzymes, antigens, antibodies, and polymer organic materials.
Relying on the key common technology platform established independently, it has successively entered biological research, in vitro diagnostics, and biomedicine.
In other business areas, it is one of the few domestic R&D and innovative enterprises with independent and controllable upstream technology development capabilities and terminal product production capabilities, intelligently manufacturing "biochips" to provide source power for the development of the biotechnology industry
.
Dizhe Pharmaceutical, a pharmaceutical innovation company that recently landed on the Science and Technology Innovation Board, has a new market value of more than 10 billion yuan, reaching 16.
4 billion yuan
.
The company is a biomedical industry company that adopts the fifth set of listing standards.
With its own translational scientific research capabilities and technology platform, the company explores the relationship between the clinical characteristics of the disease and possible abnormal driver genes and protein structures to launch First-in- Class and therapeutic methods with breakthrough potential as the goal, and strive to fill the unmet clinical needs
.
In addition, a group of Hong Kong stock companies or listed companies were split and listed on the Sci-Tech Innovation Board this year.
For example, on October 28, the "A Split A" company-Chengda Bio-tech was listed on the Sci-Tech Innovation Board.
.
The company is a subsidiary of Liaoning Chengda University and a global rabies vaccine giant.
After its listing, it has received great attention in the industry; on June 25, Changchun High-tech Holdings subsidiary Beike Biotech was successfully listed on the Science and Technology Innovation Board; another example , The domestic orthopedics giant Weigao Orthopedics also spin-off and listed on the Science and Technology Innovation Board on June 30 this year
.
It is worth mentioning that this year, many pharmaceutical companies listed on the Science and Technology Innovation Board broke their shares on the first day of listing.
For example, Dizhe Pharmaceuticals broke the issue on the first day of listing on December 10, and the intraday drop was once more than 20%
.
As of the close, Dizhe Pharmaceuticals had fallen by 21.
83%, quoting 41.
10 yuan and a turnover of 198 thousand; Chengda Biotech’s issue price was as high as 110 yuan on the day when it was listed on the Sci-tech Innovation Board.
The signing loss exceeded 10,000 yuan; Hualan shares were listed on the ChiNext of the Shenzhen Stock Exchange on November 1, with an issue price of 58.
08 yuan per share, and a P/E ratio of 101.
4 times
.
But it also fell below the issue price on the first day of listing
.
Industry insiders believe that the pharmaceutical and biological industry is a research and development-driven industry, which is in line with the positioning attributes of the science and technology innovation board
.
The break of new stocks means that the market is becoming more rational, which will help guide market investors to correct value investment concepts
.
Compared with traditional pharmaceutical companies, the future layout of innovative pharmaceutical companies will be recognized by the market and their valuations will become higher and higher
.
.
Now, it has been three years since the launch of the Sci-tech Innovation Board in 2019.
In these three years, the number of pharmaceutical and biological companies listed on the Sci-tech Innovation Board has continued to hit new highs, from 14 listed in 2019 to 28 in 2020.
Up to now, the number of pharmaceutical companies that have successfully listed on the Science and Technology Innovation Board has reached 34
.
In summary, the sci-tech innovation board pharmaceutical companies listed this year include Novartis, Dizhe Pharmaceutical, Zhijiang Biological, Chengda Biological, Beike Biological, Olin Biological, Haoyuan Pharmaceutical, etc.
, mainly focusing on chemical pharmaceuticals and medical devices.
Subdivisions such as, biological products, medical services, etc.
, each have their own characteristics, and have also revealed "hard technology" in R&D
.
In terms of market value, there are 13 pharmaceutical companies with a new market value of more than 10 billion yuan
.
Among them, the bio-reagent giant Novartis, which was listed on November 15 this year, has a market value of 46.
273 billion yuan
.
This is a biotechnology company that conducts technology research and development and product development around functional proteins such as enzymes, antigens, antibodies, and polymer organic materials.
Relying on the key common technology platform established independently, it has successively entered biological research, in vitro diagnostics, and biomedicine.
In other business areas, it is one of the few domestic R&D and innovative enterprises with independent and controllable upstream technology development capabilities and terminal product production capabilities, intelligently manufacturing "biochips" to provide source power for the development of the biotechnology industry
.
Dizhe Pharmaceutical, a pharmaceutical innovation company that recently landed on the Science and Technology Innovation Board, has a new market value of more than 10 billion yuan, reaching 16.
4 billion yuan
.
The company is a biomedical industry company that adopts the fifth set of listing standards.
With its own translational scientific research capabilities and technology platform, the company explores the relationship between the clinical characteristics of the disease and possible abnormal driver genes and protein structures to launch First-in- Class and therapeutic methods with breakthrough potential as the goal, and strive to fill the unmet clinical needs
.
In addition, a group of Hong Kong stock companies or listed companies were split and listed on the Sci-Tech Innovation Board this year.
For example, on October 28, the "A Split A" company-Chengda Bio-tech was listed on the Sci-Tech Innovation Board.
.
The company is a subsidiary of Liaoning Chengda University and a global rabies vaccine giant.
After its listing, it has received great attention in the industry; on June 25, Changchun High-tech Holdings subsidiary Beike Biotech was successfully listed on the Science and Technology Innovation Board; another example , The domestic orthopedics giant Weigao Orthopedics also spin-off and listed on the Science and Technology Innovation Board on June 30 this year
.
It is worth mentioning that this year, many pharmaceutical companies listed on the Science and Technology Innovation Board broke their shares on the first day of listing.
For example, Dizhe Pharmaceuticals broke the issue on the first day of listing on December 10, and the intraday drop was once more than 20%
.
As of the close, Dizhe Pharmaceuticals had fallen by 21.
83%, quoting 41.
10 yuan and a turnover of 198 thousand; Chengda Biotech’s issue price was as high as 110 yuan on the day when it was listed on the Sci-tech Innovation Board.
The signing loss exceeded 10,000 yuan; Hualan shares were listed on the ChiNext of the Shenzhen Stock Exchange on November 1, with an issue price of 58.
08 yuan per share, and a P/E ratio of 101.
4 times
.
But it also fell below the issue price on the first day of listing
.
Industry insiders believe that the pharmaceutical and biological industry is a research and development-driven industry, which is in line with the positioning attributes of the science and technology innovation board
.
The break of new stocks means that the market is becoming more rational, which will help guide market investors to correct value investment concepts
.
Compared with traditional pharmaceutical companies, the future layout of innovative pharmaceutical companies will be recognized by the market and their valuations will become higher and higher
.
